In the midst of the month-to-month printed FCF Life Sciences Enterprise Capital Monitor – Europe, the FCF Life Sciences workforce analyses the present sentiments in European life sciences enterprise capital funding per subsector.
In September 2021, a unfavorable development in enterprise capital financing actions was noticed in all three subsectors Biotech, MedTech and HealthTech.